Table 2.
Description of bacterial isolates per species, source material and resistance patterns against selected antibiotics in setting n.2 (30 August–30 September 2021).
| Species | K. pneumoniae | E. coli |
|---|---|---|
| Number of bacterial isolates Total n = 14 |
8 | 6 |
| Department | ||
| Hematology | 100% (8/8) | 0% |
| Interventional oncology | 0% | 100% (6/6) |
| Source material | ||
| Urine | 0% | 100% (6/6) |
| Blood | 25% (2/8) | 0% |
| Rectal swab | 75% (6/8) | 0% |
| Resistance to antibiotics | ||
| 50% (4/8) MDR | 33.3% (2/6) ESBL | |
| Ampicillin | 33.3% (2/6) | |
| Amoxicillin–clavulanic Acid | 50% (4/8) | 33.3% (2/6) |
| Piperacillin–tazobactam | 50% (4/8) | 33.3% (2/6) |
| Cefotaxime | 50% (4/8) | 33.3% (2/6) |
| Ceftazidime | 50% (4/8) | 33.3% (2/6) |
| Carbapenems (imipenem or meropenem) | 50% (4/8) | 0% |
| Ceftazidime–avibactam | 50% (4/8) | |
| Amikacin | 50% (4/8) | 0% |
| Gentamycin | 50% (4/8) | 0% |
| Fluoroquinolones (ciprofloxacin or levofloxacin) | 50% (4/8) | 0% |
| Trimethoprim–sulfamethoxazole | 50% (4/8) | |
| Nitrofurantoin | 0% | |
| Colistin | 0% | |